Antihepatotoxic Activity of Liposomal Silibinin

The liposomal form of silibinin was obtained, and its antihepatotoxic activity in mice was studied using a model of acute toxic hepatitis caused by injection of carbon tetrachloride or paracetamol. It was shown that the use of the drug in therapy or prevention regimens leads to normalization of leve...

Full description

Saved in:
Bibliographic Details
Published inBioNanoScience Vol. 8; no. 2; pp. 581 - 586
Main Authors Lutsenko, Sergey V., Gromovykh, Tatiana I., Krasnyuk, Ivan I., Vasilenko, Ivan A., Feldman, Nataliya B.
Format Journal Article
LanguageEnglish
Published New York Springer US 01.06.2018
Springer Nature B.V
Subjects
Bioavailability
Biological and Medical Physics
Biomaterials
Biophysics
Carbon tetrachloride
Circuits and Systems
Engineering
Hepatitis
Nanotechnology
Paracetamol
Proteins
Rodents
Silibinin
Transaminases
Hepatitis
Drug delivery systems
Liposomes
Silibinin
Online AccessGet full text

Cover

More Information
Summary:The liposomal form of silibinin was obtained, and its antihepatotoxic activity in mice was studied using a model of acute toxic hepatitis caused by injection of carbon tetrachloride or paracetamol. It was shown that the use of the drug in therapy or prevention regimens leads to normalization of levels of transaminases and total protein in the blood of experimental animals. The results of the study showed that liposomal silibinin when administered intravenously shows a more pronounced hepatoprotective effect compared to intragastric administration of free silibinin. Thus, the effectiveness of the therapeutic action of silibinin can be significantly increased by using its liposomal form. Liposomal drug, in contrast to native silibinin, can be injected directly into the blood that significantly increases its bioavailability.
ISSN:2191-1630
2191-1649
DOI:10.1007/s12668-018-0512-9